1998
DOI: 10.1159/000331531
|View full text |Cite
|
Sign up to set email alerts
|

ASCUS and AGUS Criteria

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
1
2

Year Published

1998
1998
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 87 publications
(10 citation statements)
references
References 15 publications
0
7
1
2
Order By: Relevance
“…ASCUS is the term used by patholo-gists to denote cellular changes that are more marked than that attributable to reactive changes but that are quantitatively or qualitatively insufficient for a definitive diagnosis of SIL. [10131415] Ten (9.8%) of the Pap smears showed features of ASCUS, with enlargement of the nucleus (to 2.5–3 times the normal intermediate cell nucleus) and a slight increase in the nuclear/cytoplasmic ratio. There was marked variation in nuclear size and shape.…”
Section: Discussionmentioning
confidence: 99%
“…ASCUS is the term used by patholo-gists to denote cellular changes that are more marked than that attributable to reactive changes but that are quantitatively or qualitatively insufficient for a definitive diagnosis of SIL. [10131415] Ten (9.8%) of the Pap smears showed features of ASCUS, with enlargement of the nucleus (to 2.5–3 times the normal intermediate cell nucleus) and a slight increase in the nuclear/cytoplasmic ratio. There was marked variation in nuclear size and shape.…”
Section: Discussionmentioning
confidence: 99%
“…Secondly, the differential diagnosis of AGC is diverse, as it encompasses a wide spectrum of cellular changes ranging from a variety of benign or reactive processes (75%) to preneoplastic or neoplastic pathology (25%), involving various cell types [2]. Thus, the literature reports AGC as an uncommon interpretation in most laboratories, ranging from 0.18 to 0.74% [3,4]. …”
Section: Introductionmentioning
confidence: 99%
“…1 Several different methods of ASCUS risk stratification have been put forth in the recent past, including such designations as ASCUS (favor reactive), ASCUS (favor dysplastic) 2 and, more recently, as part of the International Academy of Cytology consensus conference held in Hawaii in 1997, ASCUS (cannot rule out high grade SIL or low grade SIL [LSIL]). 3 As one might imagine, using the various stratification schemes allows some risk assessment; however, the percentages of follow-up SIL and HSIL cases differs widely between the studies performed. [4][5][6] Therefore, we would make the recommendation that cytologists stratify ASCUS patients into groups where follow-up SIL rates are expected to be different, as Dr. Frankel suggests, but we would not feel comfortable placing specific percentages on SIL association/progression.…”
Section: Drs Sheils and Wilbur Replymentioning
confidence: 99%